Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of 18F-fluoroacetate (18F-FACE) in non-human primates

Molecular Imaging and Biology

Volumn 14, Issue 2, 2012, Pages 213-224

  Nishii, Ryuichi ^a,b   Tong, William ^a   Wendt III, Richard ^a   Soghomonyan, Suren ^a   Mukhopadhyay, Uday ^a   Balatoni, Julius ^a   Mawlawi, Osama ^a   Bidaut, Luc ^a,c   Tinkey, Peggy ^a   Borne, Agatha ^a   Alauddin, Mian ^a   Gonzalez Lepera, Carlos ^a   Yang, Bijun ^a   Gelovani, Juri G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Dundee ^*  (Japan)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Non human primate; Positron emission tomography; Radiation dosimetry; Toxicology

Indexed keywords

FLUORINE 18; FLUOROACETIC ACID F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG UPTAKE; ELECTROCARDIOGRAM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE ANALYSIS; IMAGE DISPLAY; MALE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RHESUS MONKEY; TOXICITY TESTING; URINALYSIS; WHOLE BODY IMAGING;

ANIMALIA; MACACA MULATTA; PRIMATES;

EID: 84861482013     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0485-3     Document Type: Article

References (61)

1. Hustinx R, Benard F, Alavi A (2002) Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32:35-46 (Pubitemid 34112941)
2. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808 (Pubitemid 40525178)
3. Ide M (2006) Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging 50:23-27
4. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S-150S
5. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
6. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J (2008) Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 35:2294-2303
7. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J (2008) Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 122:2726-2734 (Pubitemid 351631374)
8. Bouchelouche K, Oehr P (2008) Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol 20:321-326 (Pubitemid 351507554)
9. Kumar R, Zhuang H, Alavi A (2004) PET in the management of urologic malignancies. Radiol Clin North Am 42:1141-1153, ix (Pubitemid 39361465)
10. Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2010) Functional imaging of renal cell carcinoma. Nat Rev Urol 7:258-266
11. Wolfort RM, Papillion PW, Turnage RH, Lillien DL, Ramaswamy MR, Zibari GB (2011) Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg 95:67-75
12. Ott K, Herrmann K, Krause BJ, Lordick F (2008) The value of PET imaging in patients with localized gastroesophageal cancer. Gastrointest Cancer Res 2:287-294
13. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ (2011) Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 17:43-49
14. Nanni C, Fantini L, Nicolini S, Fanti S (2010) Non FDG PET. Clin Radiol 65:536-548
15. Pike VW, Eakins MN, Allan RM, Selwyn AP (1982) Preparation of [1-11C]acetate-an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot 33:505-512
16. Schelbert HR (2000) PET contributions to understanding normal and abnormal cardiac perfusion andmetabolism.Ann Biomed Eng 28:922-929
17. Timmer SA, Germans T, Gotte MJ, Russel IK, Dijkmans PA, Lubberink M, ten Berg JM, ten Cate FJ, Lammertsma AA, Knaapen P, van Rossum AC (2010) Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging 37:779-788
18. 11C] acetate for measuring myocardial blood flow: studies in normal subjects and patients with hypertrophic cardiomyopathy. J Nucl Cardiol 17:264-275
19. 11C-acetate PET imaging of prostate cancer. J Nucl Med 43:181-186
20. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44:549-555
21. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN (2002) Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 29:1380-1384 (Pubitemid 44392221)
22. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 30:607-611
23. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU (2006) Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67:996-1000 (Pubitemid 43956436)
24. 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Eur J Nucl Med Mol Imaging 35:942-949
25. 18F- fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 31:797
26. Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Laforest R, Siegel BA, Welch MJ (2007) 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging - in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med 48:420-428 (Pubitemid 47604928)
27. 11C]acetate in normal physiology. Eur J Nucl Med Mol Imaging 36:1453-1459
28. 18F]fluoroacetate. Int J Radiat Appl Instrum B 13:497-500
29. 18F]fluoroacetate. J Labelled Compd Radiopharm 39:395-399
30. Sun LQ, Mori T, Dence CS, Ponde DE, Welch MJ, Furukawa T, Yonekura Y, Fujibayashi Y (2006) New approach to fully automated synthesis of sodium [18 F]fluoroacetate - a simple and fast method using a commercial synthesizer. Nucl Med Biol 33:153-158 (Pubitemid 43184090)
31. Bolch WE, Eckerman KF, Sgouros G, Thomas SR (2009) MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med 50:477-484
32. Macey DJ WL, Breitz HB, Liu A, Johnson TK, Zanzonico PB (2001) A primer for radioimmunotherapy and radionuclide therapy. AAPM report no 7. http://www.aapm.org/pubs/reports/rpt-71.pdf
33. 11C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 34:181-184
34. 18F-FDG PET/CT examinations. J Nucl Med 46:608-613
35. Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, Itoh M, Miyake M,Watanuki S (1998) Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography andmagnetic resonance imaging. Eur J NuclMed 25:565-574 (Pubitemid 28297830)
36. 11C-acetate whole-body PET. J Nucl Med 45:1233-1236
37. Anonymous (1998) Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 28:1-126
38. Kase KR (2004) Radiation protection principles of NCRP. Health Phys 87:251-257
39. 18F]FAc in a sarcomaand inflammation-bearing mouse model. Nucl Med Biol 36:305-312
40. Tecle B, Casida JE (1989) Enzymatic defluorination and metabolism of fluoroacetate, fluoroacetamide, fluoroethanol, and (-)-erythro-fluorocitrate in rats and mice examined by 19F and 13C NMR. Chem Res Toxicol 2:429-435 (Pubitemid 20048265)
41. 18F-fluoroacetate. J Nucl Med 50:982-990
42. Muir D, Berl S, Clarke DD (1986) Acetate and fluoroacetate as possible markers for glial metabolism in vivo. Brain Res 380:336-340 (Pubitemid 16015552)
43. Clarke DD (1991) Fluoroacetate and fluorocitrate: mechanism of action. Neurochem Res 16:1055-1058
44. Peters R, Wakelin RW (1953) Biochemistry of fluoroacetate poisoning; the isolation and some properties of the fluorotricarboxylic acid inhibitor of citrate metabolism. Proc R Soc Lond B Biol Sci 140:497-507
45. Proudfoot AT, Bradberry SM, Vale JA (2006) Sodium fluoroacetate poisoning. Toxicol Rev 25:213-219
46. Lauble H, Kennedy MC, Emptage MH, Beinert H, Stout CD (1996) The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. Proc Natl Acad Sci USA 93:13699-13703 (Pubitemid 26424182)
47. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763-777 (Pubitemid 47469806)
48. Lopes-Cardozo M, Mulder I, van Vugt F, Hermans PG, van den Bergh SG, Klazinga W, de Vries-Akkerman E (1975) Aspects of ketogenesis: control and mechanism of ketone-body formation in isolated rat-liver mitochondria. Mol Cell Biochem 9:155-173
49. Fenselau A, Wallis K, Morris HP (1976) Subcellular localization of acetoacetate coenzyme A transferase in rat hepatomas. Cancer Res 36:4429-4433
50. Yamashita K, Yada H, Ariyoshi T (2004) Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. J Toxicol Sci 29:155-166 (Pubitemid 38855928)
51. Goh CS, Hodgson DR, Fearnside SM, Heller J, Malikides N (2005) Sodium monofluoroacetate (compound 1080) poisoning in dogs. Aust Vet J 83:474-479
52. Goncharov NV, Jenkins RO, Radilov AS (2006) Toxicology of fluoroacetate: a review, with possible directions for therapy research. J Appl Toxicol 26:148-161
53. Gajdusek DC, Luther G (1950) Fluoroacetate poisoning a review and report of a case. Am J Dis Child 79:310-320
54. Harrisson JW, Ambrus JL, Ambrus CM (1952) Fluoroacetate (1080) poisoning. Ind Med Surg 21:440-442
55. Harrisson JW, Ambrus JL, Ambrus CM, Rees EW, Peters RH Jr, Reese LC (1952) Acute poisoning with sodium fluoroacetate (compound 1080). J Am Med Assoc 149:1520-1522
56. Vartiainen T, Gynther J (1984) Fluoroacetic acid in guar gum. Food Chem Toxicol 22:307-308 (Pubitemid 14105399)
57. Savarie P (1984) Toxic characteristics of fluorocitrate, the toxic metabolite of compound 1080. In: 11th Vertebrate Pest Conference University of Nebraska, Lincoln, University of Nebraska, Lincoln, pp 132-137
58. Carrell HL, Glusker JP, Villafranca JJ, Mildvan AS, Dummel RJ, Kun E (1970) Fluorocitrate inhibition of aconitase: relative configuration of inhibitory isomer by x-ray crystallography. Science 170:1412-1414
59. Villafranca JJ, Platus E (1973) Fluorocitrate inhibition of aconitase. Reversibility of the inactivation. Biochem Biophys Res Commun 55:1197-1207
60. Brand MD, Evans SM, Mendes-Mourao J, Chappell JB (1973) Fluorocitrate inhibition of aconitate hydratase and the tricarboxylate carrier of rat liver mitochondria. Biochem J 134:217-224
61. Eanes RZ, Kun E (1974) Inhibition of liver aconitase isozymes by (-)-erythro-fluorocitrate. Mol Pharmacol 10:130-139